Peptides for Inflammation
Research overview of peptides studied for inflammation and inflammatory conditions. KPV, LL-37, BPC-157, and anti-inflammatory peptide evidence.
Research Overview
Anti-inflammatory peptide research includes both naturally occurring peptides with immunomodulatory properties and synthetic compounds designed to target inflammatory pathways. This diverse field ranges from well-characterized antimicrobial peptides to investigational compounds with limited human data.
KPV (Lys-Pro-Val), a C-terminal fragment of alpha-melanocyte stimulating hormone, has shown anti-inflammatory effects in preclinical IBD models. LL-37 and other antimicrobial peptides have dual roles in pathogen defense and inflammatory modulation. BPC-157 has been studied for various inflammatory conditions in animal models.
Most anti-inflammatory peptides remain in preclinical or early clinical development. While mechanisms are often well-characterized, the translation to human therapeutic applications generally lags behind small molecule anti-inflammatory drugs.
Key Anti-Inflammatory Peptides
KPV (Alpha-MSH Fragment)
| Aspect | Details |
|---|---|
| Origin | C-terminal fragment of α-MSH |
| Mechanism | MC1R independent, NF-κB modulation |
| Evidence | Low (primarily preclinical) |
| IBD models | Promising animal data |
LL-37 (Cathelicidin)
| Aspect | Details |
|---|---|
| Origin | Endogenous antimicrobial peptide |
| Mechanism | Immunomodulation, pathogen defense |
| Evidence | Moderate (well-characterized) |
| Applications | Research ongoing |
BPC-157 (Anti-Inflammatory Effects)
| Research Area | Evidence Level |
|---|---|
| GI inflammation | Low (rodent models) |
| Joint inflammation | Low (preclinical) |
| General anti-inflammatory | Low |
Antimicrobial Peptides (AMPs)
| Peptide | Anti-Inflammatory Research |
|---|---|
| Defensins | Dual antimicrobial/immunomodulatory |
| Lactoferricin | Inflammation models |
| Thymosin alpha-1 | Immune modulation |
Thymosin Alpha-1
Status: Approved in some countries for immune modulation
| Indication | Evidence Level |
|---|---|
| Hepatitis B/C | Moderate |
| Cancer adjuvant | Low-Moderate |
| Inflammation (general) | Low |
Evidence Limitations
- Most data from animal models
- Human trials limited
- Mechanisms often better understood than clinical outcomes
- Many peptides not approved for inflammatory conditions
Peptides Studied for Inflammation
KPV
LowLys-Pro-Val is the C-terminal tripeptide motif of alpha-MSH. KPV reduced inflammatory readouts in cell and mouse colitis models, including a PepT1 uptake study. Human drug exposure, pharmacokinetics, safety and clinical benefit remain unestablished.
LL-37
LowLL-37 is the active human cathelicidin peptide. Three topical wound trials studied native LL-37, with mixed outcomes; an oral trial used engineered bacteria expressing LL-37. These results do not establish systemic benefit.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. The peptides listed may or may not have regulatory approval. Always consult a qualified healthcare provider before making any health decisions.